Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.

Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K, Ulrich M, Anderson ME, Stone IJ, Zeng W, Jonas M, Lewis TS, Goswami M, Wang SA, Senter PD, Law CL, Feldman EJ, Benjamin DR.

Mol Cancer Ther. 2018 Feb;17(2):554-564. doi: 10.1158/1535-7163.MCT-17-0742. Epub 2017 Nov 15.

2.

Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75.

Ryan MC, Kostner H, Gordon KA, Duniho S, Sutherland MK, Yu C, Kim KM, Nesterova A, Anderson M, McEarchern JA, Law CL, Smith LM.

Br J Cancer. 2010 Aug 24;103(5):676-84. doi: 10.1038/sj.bjc.6605816. Epub 2010 Jul 27.

3.

5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.

Sutherland MK, Yu C, Anderson M, Zeng W, van Rooijen N, Sievers EL, Grewal IS, Law CL.

MAbs. 2010 Jul-Aug;2(4):440-8. Epub 2010 Jul 1.

4.

Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.

Sutherland MK, Yu C, Lewis TS, Miyamoto JB, Morris-Tilden CA, Jonas M, Sutherland J, Nesterova A, Gerber HP, Sievers EL, Grewal IS, Law CL.

MAbs. 2009 Sep-Oct;1(5):481-90. Epub 2009 Sep 15.

5.

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers.

Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber HP, Van Orden KL, Moore PA, Ruben SM, Carter PJ.

Br J Cancer. 2008 Jul 8;99(1):100-9. doi: 10.1038/sj.bjc.6604437. Epub 2008 Jun 10.

6.

Long-term culture in dexamethasone unmasks an abnormal phenotype in osteoblasts isolated from osteoporotic subjects.

Rao LG, Murray TM, Wylie JN, McBroom RJ, Sutherland MK.

J Endocrinol Invest. 2005 Nov;28(10):919-27.

PMID:
16419495
7.

Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation.

Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA.

Bone. 2004 Oct;35(4):828-35.

PMID:
15454089
8.

Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts.

Sutherland MK, Geoghegan JC, Yu C, Winkler DG, Latham JA.

Bone. 2004 Aug;35(2):448-54.

PMID:
15268896
9.

Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex.

Winkler DG, Yu C, Geoghegan JC, Ojala EW, Skonier JE, Shpektor D, Sutherland MK, Latham JA.

J Biol Chem. 2004 Aug 27;279(35):36293-8. Epub 2004 Jun 14.

10.

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.

Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA.

EMBO J. 2003 Dec 1;22(23):6267-76.

11.

Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.

Sutherland MK, Brady H, Gayo-Fung LM, Leisten J, Lipps SG, McKie JA, O'Leary E, Patnaik N, Anderson DW, Bhagwat SS, Stein B.

Calcif Tissue Int. 2003 Jun;72(6):710-6.

PMID:
14563000
12.

Effects of SP500263, a novel, potent antiestrogen, on breast cancer cells and in xenograft models.

Brady H, Desai S, Gayo-Fung LM, Khammungkhune S, McKie JA, O'Leary E, Pascasio L, Sutherland MK, Anderson DW, Bhagwat SS, Stein B.

Cancer Res. 2002 Mar 1;62(5):1439-42.

13.

Differential response of estrogen receptors alpha and beta to SP500263, a novel potent selective estrogen receptor modulator.

Brady H, Doubleday M, Gayo-Fung LM, Hickman M, Khammungkhune S, Kois A, Lipps S, Pierce S, Richard N, Shevlin G, Sutherland MK, Anderson DW, Bhagwat SS, Stein B.

Mol Pharmacol. 2002 Mar;61(3):562-8.

PMID:
11854436
15.
17.

Carboxyl-terminal parathyroid hormone peptide (53-84) elevates alkaline phosphatase and osteocalcin mRNA levels in SaOS-2 cells.

Sutherland MK, Rao LG, Wylie JN, Gupta A, Ly H, Sodek J, Murray TM.

J Bone Miner Res. 1994 Apr;9(4):453-8.

PMID:
8030432
18.

Reduction of calbindin-28k mRNA levels in Alzheimer as compared to Huntington hippocampus.

Sutherland MK, Wong L, Somerville MJ, Yoong LK, Bergeron C, Parmentier M, McLachlan DR.

Brain Res Mol Brain Res. 1993 Apr;18(1-2):32-42.

PMID:
8479289
19.

Aluminum-binding serum proteins: desferrioxamine alters serum aluminum speciation.

Favarato M, Mizzen CA, Sutherland MK, Krishnan B, Kruck TP, McLachlan DR.

Clin Chim Acta. 1992 Apr 30;207(1-2):41-55.

PMID:
1591866
20.

Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels.

Sutherland MK, Somerville MJ, Yoong LK, Bergeron C, Haussler MR, McLachlan DR.

Brain Res Mol Brain Res. 1992 Apr;13(3):239-50.

PMID:
1317496
21.

Reduction of thyroid hormone receptor c-ERB A alpha mRNA levels in the hippocampus of Alzheimer as compared to Huntington brain.

Sutherland MK, Wong L, Somerville MJ, Handley P, Yoong L, Bergeron C, McLachlan DR.

Neurobiol Aging. 1992 Mar-Apr;13(2):301-12.

PMID:
1387923
22.

Anomalous gene expression in Alzheimer disease: cause or effect.

McLachlan DR, Lukiw WJ, Mizzen C, Percy ME, Somerville MJ, Sutherland MK, Wong L.

Can J Neurol Sci. 1991 Aug;18(3 Suppl):414-8.

PMID:
1933691
23.

A correlation between gene transcriptional activity and cerebral glucose metabolism in Alzheimer's disease-affected neocortex: cause or effect?

Lukiw WJ, Handley P, Sutherland MK, Wong L, McLachlan DR.

Adv Exp Med Biol. 1991;291:249-56.

PMID:
1927687

Supplemental Content

Loading ...
Support Center